CALGARY, Alberta, Nov. 02, 2017 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce the Company’s participation in the following upcoming industry conferences.
| • American Society of Nephrology – ASN 2017 Annual Meeting | |
| Location: | New Orleans, LA. |
| Date: | November 3rd, 2017 |
| Poster 1: | “Analysis of the Plasma Proteome Reveals Dysregulation of Molecular Pathways in Patients with Stage 4 Chronic Kidney Disease” |
| Presentation Time: | 10:00am – 12:00pm CT |
| Date: | November 4th, 2017 |
| Poster 2: | “Apabetalone (RVX-208) Impacts Key Markers and Pathways Associated with Chronic Kidney Disease in Patients with Severe Renal Impairment” |
| Presentation Time: | 10:00am – 12:00pm CT |
| Meeting Link: | LINK |
| • BIO-Europe 2017 | |
| Location: | Berlin, Germany. |
| Date: | November 7th, 2017 |
| Presentation Time: | 4:45pm CEST |
| Presenting: | Mr. Donald McCaffrey, President and Chief Executive Officer |
| Conference Link: | LINK |
| • American Heart Association – AHA Scientific Sessions 2017 | |
| Location: | Anaheim, CA |
| Date: | November 13th, 2017 |
| Poster: | “Apabetalone Downregulates Factors That Promote Vascular Calcification and Contribute to Cardiovascular Events” |
| Presentation Time: | 10:30am PT |
| Meeting Link: | LINK |
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
